胰升糖素样肽1受体激动剂治疗多囊卵巢综合征的研究进展  

Research Progress of Glucagon-like Peptide-1 Receptor Agonist in the Treatment of Polycystic Ovary Syndrome

作　　者：郑灿滨 林少达[1] 杨晓平[1] ZHENG Canbin;LIN Shaoda;YANG Xiaoping(Department of Endocrinology,the First Affiliated Hospital of Shantou University Medical College,Shantou 515041,China)

机构地区：[1]汕头大学医学院第一附属医院内分泌科,广东汕头515041

出　　处：《医学综述》2018年第8期1600-1605,共6页Medical Recapitulate

摘　　要：多囊卵巢综合征(PCOS)是常见于育龄期妇女的生殖内分泌疾病,其发病机制与高雄激素血症与胰岛素抵抗相互作用、下丘脑-垂体-卵巢轴功能异常、垂体-肾上腺轴功能及中枢胰岛素受体作用异常等有关。胰高血糖素素样肽1受体激动剂(GLP-1Ra)除改善胰岛素抵抗、减轻体质量外,还调节改善高雄激素等性激素和促性腺激素水平;减轻PCOS的慢性炎症、改善糖脂代谢紊乱及生殖功能;GLP-1Ra为PCOS的治疗提供了新的治疗手段,在PCOS的病理生理作用及临床价值有待进一步研究。Polycystic ovary syndrome(PCOS)is a heterogeneous gynecologic disease which commonly affects women of reproductive ages.Altered interaction between hyperandrogenemia and insulin resistance,impaired function of hypothalamic-pituitary-ovarian axis and pituitary-adrenal axis,malfunction of central insulin receptors are factors involved.Apart from its actions on improving insulin resistance and weight control,glucagon-like peptide-1 receptor agonist(GLP-1Ra)can also modulate hyperandrogenemia,gonadotropin levels,relieve inflammation,improve carbohydrate lipid metabolism and reproductive functions of PCOS patients.GLP-1Ra offers a new treatment option for PCOS patients.The role of GLP-1Ra in PCOS pathophysiology and its clinical value for PCOS patients need further investigation.

关 键 词：胰升糖素样肽1 受体激动剂 多囊卵巢综合征 胰岛素抵抗 

分 类 号：R588.6[医药卫生—内分泌]